Vanguard Group Inc Takes $5.20 Million Position in OptimizeRx Co. (OPRX)

Vanguard Group Inc purchased a new position in shares of OptimizeRx Co. (NASDAQ:OPRX) during the third quarter, according to its most recent …

OptimizeRx logoVanguard Group Inc purchased a new position in shares of OptimizeRx Co. (NASDAQ:OPRX) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 289,123 shares of the company’s stock, valued at approximately $5,204,000. Vanguard Group Inc owned 2.41% of OptimizeRx as of its most recent filing with the SEC.

OPRX has been the subject of several analyst reports. William Blair initiated coverage on OptimizeRx in a research note on Thursday, January 3rd. They issued an “outperform” rating for the company. Zacks Investment Research raised OptimizeRx from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Friday, January 4th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $18.25.

Shares of OPRX stock traded up $0.08 during trading on Wednesday, hitting $14.37. The company’s stock had a trading volume of 45,730 shares, compared to its average volume of 57,962. The firm has a market cap of $168.74 million, a PE ratio of 287.40, a P/E/G ratio of 2.79 and a beta of 0.93. OptimizeRx Co. has a 52 week low of $2.30 and a 52 week high of $18.39.

TRADEMARK VIOLATION WARNING: This story was posted by Fairfield Current and is owned by of Fairfield Current. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.fairfieldcurrent.com/news/2019/03/06/vanguard-group-inc-takes-position-in-optimizerx-co-oprx.html.

OptimizeRx Profile

OptimizeRx Corporation provides digital health messaging to the pharmaceutical industry. The company offers a direct channel for pharmaceutical companies to communicate with healthcare providers. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-Prescribe systems to search, print, or electronically dispense directly to patients, as well as a network of pharmacies; and brand messaging services, such as various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages that could be targeted by specialty, diagnostic code, and other criteria.

Recommended Story: The basics of gap trading strategies

Institutional Ownership by Quarter for OptimizeRx (NASDAQ:OPRX)

Receive News & Ratings for OptimizeRx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OptimizeRx and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Vanguard Group Inc Takes Position in OptimizeRx Co. (OPRX)

Vanguard Group Inc bought a new position in shares of OptimizeRx Co. (NASDAQ:OPRX) during the 3rd quarter, according to its most recent …

OptimizeRx logoVanguard Group Inc bought a new position in shares of OptimizeRx Co. (NASDAQ:OPRX) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 289,123 shares of the company’s stock, valued at approximately $5,204,000. Vanguard Group Inc owned 2.41% of OptimizeRx at the end of the most recent quarter.

Shares of OPRX stock traded up $0.26 during trading on Tuesday, hitting $13.06. The company’s stock had a trading volume of 1,629 shares, compared to its average volume of 62,232. The firm has a market cap of $151.50 million, a PE ratio of -62.19, a P/E/G ratio of 2.70 and a beta of 0.93. OptimizeRx Co. has a 52 week low of $2.30 and a 52 week high of $18.39.

Several equities analysts have recently issued reports on OPRX shares. Zacks Investment Research lowered OptimizeRx from a “buy” rating to a “hold” rating in a report on Tuesday, October 23rd. William Blair started coverage on OptimizeRx in a report on Thursday, January 3rd. They issued an “outperform” rating for the company. Five analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $18.25.

COPYRIGHT VIOLATION WARNING: “Vanguard Group Inc Takes Position in OptimizeRx Co. (OPRX)” was first reported by Fairfield Current and is the sole property of of Fairfield Current. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.fairfieldcurrent.com/news/2019/02/12/vanguard-group-inc-takes-position-in-optimizerx-co-oprx.html.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging to the pharmaceutical industry. The company offers a direct channel for pharmaceutical companies to communicate with healthcare providers. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-Prescribe systems to search, print, or electronically dispense directly to patients, as well as a network of pharmacies; and brand messaging services, such as various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages that could be targeted by specialty, diagnostic code, and other criteria.

Further Reading: QQQ ETF

Want to see what other hedge funds are holding OPRX?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptimizeRx Co. (NASDAQ:OPRX).

Receive News & Ratings for OptimizeRx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OptimizeRx and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts